StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about TPST. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2018 2018-09-30 | Q2 2018 2018-06-30 | Q3 2017 2017-09-30 | Q2 2017 2017-06-30 |
|---|---|---|---|---|
Revenue | $203.00K | $148.00K | $204.00K | $147.00K |
Operating Income | $-17.18M | $-9.37M | $-41.92M | $-32.52M |
Net Income | $-16.64M | $-9.11M | $-42.45M | $-33.08M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $49.23M | $55.53M | $82.03M | $93.89M |
Total Liabilities | $4.32M | $5.32M | $9.74M | $12.74M |
Cash & Equivalents | $31.92M | $24.60M | $24.77M | $22.94M |
Free Cash Flow OCF − CapEx | $-14.44M | $-9.71M | $-37.69M | $-27.38M |
Shares Outstanding | 35.83M | 35.79M | 35.71M | 35.69M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.